tremelimumab,durvalumab,cabozantinib
astrazeneca,pfizer
['camilla', 'durva', 'esophageal', 'cabozantinib', 'gastroesophageal']
cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: phase ib camilla trial results. &amp; colleagues #asco23 
Cell Press partners with scientists across all disciplines to publish and share work that will inspire future directions in research. #ScienceThatInspires